Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Misoprostol is a synthetic prostaglandin E1 analogue used to prevent and treat gastric and duodenal ulcers, particularly in patients taking nonsteroidal anti-inflammatory drugs (NSAIDs). It works by replacing prostaglandins that are inhibited by NSAIDs, thereby reducing gastric acid secretion and protecting the stomach lining. Misoprostol also stimulates uterine contractions and cervical ripening, making it useful for medical abortion (alone or with mifepristone or methotrexate), management of miscarriage, induction of labor, and treatment of postpartum hemorrhage. It was developed in 1973 for ulcer prevention and is included on the World Health Organization's List of Essential Medicines. Developed by Searle.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on misoprostol.